NICE green light for immunotherapy Bavencio
Merck and Pfizer’s drug will now be available on the NHS in combination with axitinib as a first-line treatment for kidney cancer
Read More
Tag: RCC
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
NICE says the combination’s cost-effectiveness estimate is higher than what is considered acceptable for NHS use
Read More
NICE backs Bavencio combo for kidney cancer
The combination of an immunotherapy with a targeted antiangiogenic therapy offers patients a novel treatment option
Read More
Opdivo/Cabometyx combo hits targets in first-line kidney cancer
The combination significantly increased progression free survival when used as a first-line treatment
Read More
Keytruda combo wins FDA approval for RCC
The approval is based on results of the KEYNOTE-426 study, in which Keytruda in combination with Inlyta was found to reduce the risk of death by nearly half compared to Sutent.
Read More
EMA validates Bavencio for review in advanced RCC
European regulators have validated Merck’s application Bavencio for review in kidney cancer.
Read More
Bavencio combo gets FDA priority review for kidney cancer
The US Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) for patients with advanced renal cell carcinoma (RCC).
Read More
Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.
Read More
EU OKs first-line use of Ipsen’s Cabometyx
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Read More
Pfizer pulls plug on Inlyta trial
Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
Read More
NICE backs EUSA’s kidney cancer drug Fotivda
The National Institute for Health and Care Excellence (NICE) has published draft guidelines backing use of EUSA Pharma’s Fotivda as a first-line treatment option for advanced renal cell carcinoma.
Read More
US ‘breakthrough’ badge for MSD/Eisai cancer combo
A combination therapy being developed by MSD and Eisai for kidney cancer has been awarded Breakthrough Designation in the US.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
